Selpercatinib – a new option for a precision approach to the treatment of medullary thyroid cancer

Authors: A. K. Plugar, N. V. Severskaya, P. A. Isaev, Yu. A. Panaseykin, V. V. Polkin, L. N. Vatina, T. A. Agababyan, S. А. Ivanov, A. D. Kaprin

Source: Опухоли головы и шеи, Vol 14, Iss 4, Pp 77-85 (2024)

Subject Terms: medullary thyroid cancer, selpercatinib, ret gene mutations, targeted therapy, progression-free survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://ogsh.abvpress.ru/jour/article/view/1028; https://doaj.org/toc/2222-1468; https://doaj.org/toc/2411-4634

Access URL: https://doaj.org/article/0bec7bab9e80401fa15249dc3f47496d

Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database

Authors: Jiancheng Qian, Shuohan Zhang, Cheng Jiang

Source: BMC Cancer, Vol 24, Iss 1, Pp 1-13 (2024)

Subject Terms: Selpercatinib, Adverse event, FAERS, Hepatobiliary disorders, Hypersensitivity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/4c229e639f5c44bfacf82aa03b774dd7

Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)

Authors: Rachel E. Reingold, MD, Rose Parisi, MD, MBA, Guilherme Harada, MD, Andrea P. Moy, MD, George Dranitsaris, PhD, Jasmine H. Francis, MD, Julia Canestraro, OD, FAAO, Julia A. Lester, MPH, Lauren A. Kaplanis, RN, Dazhi Liu, PharmD, BCOP, Mario E. Lacouture, MD, Alexander Drilon, MD

Source: JTO Clinical and Research Reports, Vol 6, Iss 3, Pp 100792- (2025)

Subject Terms: Selpercatinib, Mucocutaneous adverse event, RET fusion, RET mutation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364325000086; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/86fff4dcdf624235bbc62f09b66ba6e9

Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms

Authors: Arianna Marinello, MD, Claudia Parisi, MD, Damien Vasseur, PhD, David Combarel, PharmD, Juliette Bihoreau, NP, Pernelle Lavaud, MD, Rémy Ezzedine, MD, Lodovica Zullo, MD, Luc Friboulet, PhD, Gerard Zalcman, MD, PhD, Antoine Italiano, MD, PhD, Benjamin Besse, MD, PhD, Mihaela Aldea, MD, PhD

Source: JTO Clinical and Research Reports, Vol 6, Iss 3, Pp 100773- (2025)

Subject Terms: EGFR-mutated NSCLC, RET fusion, BRAF V600E, Selpercatinib, Trametinib, Case report, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364324001437; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/342ea336baed47408d1a5e3b6965bb2f

Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer

Authors: Jun Sakakibara-Konishi, Hirofumi Takahashi, Kenichiro Ito, Tomoo Ikari, Yasuyuki Ikezawa, Hidenori Kitai, Megumi Furuta, Yuta Takashima, Tetsuaki Shoji, Masahide Fukudo, Satoshi Konno

Source: Respiratory Medicine Case Reports, Vol 53, Iss , Pp 102176- (2025)

Subject Terms: Non-small cell lung cancer, RET-rearranged lung cancer, Selpercatinib, Diseases of the respiratory system, RC705-779

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2213007125000127; https://doaj.org/toc/2213-0071

Access URL: https://doaj.org/article/5af3ea18c9b24f948f0d8a778700eb6c

RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer

Authors: Charlotte K. Kindt, Sidse Ehmsen, Sofie Traynor, Benedetta Policastro, Nikoline Nissen, Mie K. Jakobsen, Monique F. Hundebøl, Lene E. Johansen, Martin Bak, Elsa Arbajian, Johan Staaf, Henrik J. Ditzel, Carla L. Alves

Source: Frontiers in Oncology, Vol 14 (2025)

Subject Terms: estrogen receptor-positive breast cancer, RET, selpercatinib, CDK4/6 inhibitor, drug resistance, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1497093/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/f6678566e7304a6384e1de32ca408baa

Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case

Authors: Raffaella Pagliaro, Paola Maria Medusa, Fabiana Vitiello, Luigi Aronne, Susan F. M. Campbell, Fabio Perrotta, Andrea Bianco

Source: Frontiers in Oncology, Vol 14 (2025)

Subject Terms: lung adenocarcinoma, RET fusion, selpercatinib, targeted therapy, precision medicine, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1500449/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/a5ff7c9fb2d54f969b8c5af808c6b96a

Research on detection methods of related substances and degradation products of the antitumor drug selpercatinib

Authors: Jingjing Xiang, Liangliang Cai, Qin Wang, Yonghong Zhu, Yong Han

Source: Frontiers in Chemistry, Vol 12 (2025)

Subject Terms: selpercatinib, related substances, degradation products, method development, method validation, liquid chromatography, Chemistry, QD1-999

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fchem.2024.1534132/full; https://doaj.org/toc/2296-2646

Access URL: https://doaj.org/article/ec7b3d52d9b1437ab072381944f7dfc5

A case of organizing pneumonia in rearranged during transfection fusion‐positive lung adenocarcinoma treated with selpercatinib

Authors: Hiroki Ohkoshi, Masafumi Saiki, Nozomu Takahashi, Kenta Homma, Satoshi Furuya, So Shimamura, Chisa Omori, Yuki Hoshino, Yoshinori Uchida, Shinnosuke Ikemura, Kenzo Soejima

Source: Thoracic Cancer, Vol 15, Iss 25, Pp 1863-1866 (2024)

Subject Terms: organizing pneumonia, RET fusion, selpercatinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1759-7706; https://doaj.org/toc/1759-7714

Access URL: https://doaj.org/article/716797d0b1244a2fadca993c1d2f1f18

Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model

Authors: Khatri, Ujjwol ^{a, b}, Gouda, Mohamed A. ^c, Pandey, Shriya ^{a, b}, Chauhan, Neeraj K. ^{a, b}, Shen, Tao ^{a, b}, Hu, Xueqing ^{a, b}, Li, Min ^{a, d}, Huang, Suming ^e, Subbiah, Vivek ^{c, f, ⁎⁎}, Wu, Jie ^{a, b, ⁎}

Source: In Cancer Letters 28 February 2025 611

Rearranged during transfection (RET) lung cancer – Update on targeted therapies

Authors: Mullally, W.J. ^{a, ⁎}, O’Leary, C.G. ^b, O’Byrne, K.J. ^{a, c, d, ⁎}

Source: In Lung Cancer February 2025 200

Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in RET Fusion-Positive NSCLC

Authors: Zhou, Caicun ^{a, ∗}, Novello, Silvia ^{b, c}, Garrido, Pilar ^d, Dooms, Christophe ^e, Alatorre-Alexander, Jorge ^f, Reinmuth, Niels ^g, Worthy, Gill ^h, Cocks, Kim ^h, Williams, Justin ⁱ, Han, Hongmei ⁱ, Uh, Minji K. ⁱ, Payakachat, Nalin ⁱ, Gilligan, Adrienne M. ⁱ, Goto, Koichi ^j

Source: In JTO Clinical and Research Reports February 2025

Case report: Eczematous adverse drug reaction after selpercatinib treatment

Authors: Bingrun Li, Peng Cao, Wenjing Xu, Litao Zhang

Source: Frontiers in Oncology, Vol 14 (2024)

Subject Terms: eczematous reaction, adverse drug reaction, selective RET inhibitor, selpercatinib, glucocorticoid, case report, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1475541/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/2ac440ffeba74a089e143475d41d2e87

Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report

Authors: Illaa Smesseim, MD, Tijmen van der Wel, MD, Sushil K. Badrising, MD, PhD

Source: JTO Clinical and Research Reports, Vol 5, Iss 12, Pp 100730- (2024)

Subject Terms: RET, Selpercatinib, Non–small-cell lung carcinoma, RET fusion, NSCLC, Case Report, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364324001000; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/b85dc2fa0d424aee88a8beffee93b8fd

Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review

Authors: Kaidiriye Setiwalidi, Yimeng Li, Yuyan Ma, Zhanpeng Hao, Yujia Zhao, Yuxin Zhang, Xuan Liang, Tao Tian, Zhiping Ruan, Yu Yao, Xiao Fu

Source: Frontiers in Oncology, Vol 14 (2024)

Subject Terms: NSCLC, RET, pralsetinib, selpercatinib, invasive aspergillosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1431908/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/bf72cd5c8d3d4d33930a7185f492a834

Unique hypersensitivity syndrome secondary to selpercatinib

Authors: Siddharth Srikakolapu, MD, Dev R. Sahni, MD, Lauren M. Madigan, MD

Source: JAAD Case Reports, Vol 50, Iss , Pp 138-140 (2024)

Subject Terms: drug-induced hypersensitivity syndrome, drug reaction with eosinophilia and systemic symptoms, hypersensitivity, oncodermatology, selpercatinib, Dermatology, RL1-803

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2352512624002297; https://doaj.org/toc/2352-5126

Access URL: https://doaj.org/article/00211d2071f04979bf191c1d3f93fd13

Separation, characterization and cytotoxicity of unknown forced degradation impurity of selpercatinib using Prep-LC, HRMS and NMR

Authors: Wang, Qin ^a, Wu, Wenyi ^b, Sun, Rongwei ^c, Cai, Liangliang ^{a, d, ⁎}

Source: In Journal of Pharmaceutical and Biomedical Analysis 15 June 2025 258

Rapid and sensitive HPLC with fluorescence detection method for quantifying selpercatinib in liver microsomes and rat plasma: Implications for drug-drug interaction studies

Authors: Zayed, Aref L. ^{a, ⁎}, Alshekhhossin, Aysheh M. ^a, Al Kilani, Omar M. ^a, Jaber, Sana'a A. ^a, Dawood, Leen L. ^a, Al Hroot, Jomana ^a, Alzarieni, Kawthar Z. ^a

Source: In Journal of Chromatography B 15 April 2025 1256

LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC

Authors: Lee ATM, Ou SI

Source: Lung Cancer: Targets and Therapy, Vol Volume 15, Pp 75-80 (2024)

Subject Terms: libretto-431, selpercatinib, ret fusion positive nsclc, pralsetinib, immunotherapy in never-smokers, relative dose intensity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.dovepress.com/libretto-431-confirming-the-superiority-of-selpercatinib-to-chemothera-peer-reviewed-fulltext-article-LCTT; https://doaj.org/toc/1179-2728

Access URL: https://doaj.org/article/239290dacf054e06a8a3547851c8fc4e

Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system

Authors: Qiong Jie, Yuanyuan Li, Li Jing, Jinjin Chen, Yang Li

Source: Frontiers in Pharmacology, Vol 15 (2024)

Subject Terms: pralsetinib, selpercatinib, adverse drug reactions, FAERS, pharmacovigilance, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2024.1424980/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/115363d2b28a404aadedd91fecaebd8a